Development of therapeutic HPV vaccines

HPV vaccines prophylactic, not therapeutic.

Development of prophylactic HPV vaccines.

Since several years it has been accepted that persistent infection with certain (so called-high risk: HR) types of Human papillomaviruses (HPV) represents a strong risk factor for cervical cancer. The most frequent HR HPV types 16 and 18 account for about 70% of this tumour, which is the second most frequent malignancy in women worldwide. Several studies in animal papillomavirus models revealed...

Chapter 7 Therapeutic Human Papillomavirus ( HPV ) Vaccines

Cervical cancer trends to occur in midlife. Most cases are found in women younger than 50. More than 15% of cases of cervical cancer are found in women over 65 but, these cancers rarely arrise in women who have regular tests for cervical cancer screening before they were 65. The most important etiological factor in cervical cancer and precursor lesions is persistent infection by HPV. Thus, an e...

Chapter 11: HPV vaccines: commercial research & development.

We are now in the fortunate position of having two highly promising human papillomavirus (HPV) vaccines in the pipeline. Amidst the excitement of anticipating what these vaccines may be able to offer, it is worth pausing to look back at how the vaccine development story unfolded from an industrial perspective, since without the massive commitment shown by manufacturers over the last decade, wit...

8. Impact of prophylactic HPV vaccination on the cervical cancer incidence and mortality. Perspectives for development of therapeutic HPV vaccines

In this Chapter we will discuss the current status of the prophylactic HPV vaccination, the introduction of HPV prophylactic vaccination and its impact on the cervical cancer incidence and mortality, challenges of the HPV vaccination in the developing world, screening post vaccination and the secondgeneration HPV prophylactic vaccines, as well as, the development of new therapeutic vaccines and...